Dual inhibition of TNF-α and IL-1β signaling through BIG2 ameliorates osteoarthritis in mouse and primate models
Science Translational Medicine · 11.11.2026 · 18 (875)
DOI: 10.1126/scitranslmed.aec8494 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 11.11.2026. Verfasst von Wenyu Fu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics and Rehabilitation, Yale University School of Medicine, New Haven, CT, USA. Hauptthemen laut MEDLINE: Interleukin-1beta, Tumor Necrosis Factor-alpha, Signal Transduction, Osteoarthritis. Die Arbeit nennt 89 Literaturangaben. Gefördert von: National Institutes of Health.
Abstract (Originalsprache)
Osteoarthritis (OA), a leading cause of disability, is characterized by chronic low-grade inflammation and metabolic dysregulation in chondrocytes. TNF-α and IL-1β are key inflammatory drivers in OA pathogenesis, but clinical trials targeting them individually have been unsuccessful, highlighting the potential need for dual-targeting strategies. By screening a US Food and Drug Administration–approved drug library, we identified dabigatran, a thrombin inhibitor, as a potent dual suppressor of TNF-α and IL-1β signaling that restored chondrocyte metabolism. In preclinical OA models, including both mice and cynomolgus macaques, dabigatran attenuated cartilage degeneration, alleviated pain, and improved joint function. To elucidate the molecular mechanisms, we performed biochemical copurification coupled with mass spectrometry, identifying brefeldin A–inhibited guanine nucleotide–exchange protein 2 (BIG2) as a previously unknown dabigatran-binding target. Mechanistically, dabigatran binds to BIG2, promoting BIG2-dependent TNFR1 release to dampen TNF-α signaling while enhancing BIG2-mediated IL-1R1 degradation through the autophagy-lysosome pathway to limit IL-1β effects. These findings establish BIG2-mediated receptor trafficking and membrane dynamics as a regulatory node that concurrently inhibits TNF-α and IL-1β signaling, suggesting this pathway as a potential therapeutic strategy for OA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedics and Rehabilitation, Yale University School of Medicine, New Haven, CT, USA.
- Department of Orthopedic Surgery, New York University Grossman School of Medicine, New York, NY, USA.
- Department of Orthopedics, First Affiliated Hospital of Jinan University, Guangzhou, China.
- Guangdong Provincial Key Laboratory of Spine and Spinal Cord Reconstruction, Fifth Affiliated Hospital of Jinan University, Heyuan, China.
ORCID-Profile: Wenyu Fu, Ronghan Liu, Jin Wo, Xin Liu, Shuya Wang, Wenhao Song, Haoran Zhu, Yazhou Cui, Chao Wang, Lei Zhang, Ran Schwarzkopf, Irvin Oh, Daniel H Wiznia, Guodong Sun, Chuan-Ju Liu
Förderung
- National Institutes of Health
Zitieren
APA
Fu, W., Liu, R., Wo, J., Liu, X., Wang, S., Song, W., Zhu, H., Cui, Y., Chen, Y., Wang, C., Zhang, L., Schwarzkopf, R., Oh, I., Wiznia, D. H., Sun, G., & Liu, C. J. (2026). Dual inhibition of TNF-α and IL-1β signaling through BIG2 ameliorates osteoarthritis in mouse and primate models. Science Translational Medicine, 18(875). https://doi.org/10.1126/scitranslmed.aec8494
Vancouver
Fu W, Liu R, Wo J, Liu X, Wang S, Song W, et al. Dual inhibition of TNF-α and IL-1β signaling through BIG2 ameliorates osteoarthritis in mouse and primate models. Science Translational Medicine. 2026;18(875). doi:10.1126/scitranslmed.aec8494
BibTeX
@article{Fu2026,
author = {Fu, Wenyu and Liu, Ronghan and Wo, Jin and Liu, Xin and Wang, Shuya and Song, Wenhao and Zhu, Haoran and Cui, Yazhou and Chen, Yuehong and Wang, Chao and Zhang, Lei and Schwarzkopf, Ran and Oh, Irvin and Wiznia, Daniel H and Sun, Guodong and Liu, Chuan-Ju},
title = {Dual inhibition of TNF-α and IL-1β signaling through BIG2 ameliorates osteoarthritis in mouse and primate models},
journal = {Science Translational Medicine},
year = {2026},
volume = {18},
number = {875},
doi = {10.1126/scitranslmed.aec8494}
}
EUVIMED